Pfizer CEO Albert Bourla supports Trump administration at PhRMA Forum, while CDC postpones vaccine advisory meeting. Atomwise names Steve Worland as CEO, and Biogen licenses Dravet drug.
The FDA on Friday approved Mirum Pharmaceuticals' Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease.
Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave of departures at the agency and across the federal health infrastructure as ...
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...
The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, ...
UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. “The ACIP meeting will ...
Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four ...
Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma announced earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback